Entering text into the input field will update the search result below

Biogen, Sobi haemophilia treatment maintains low bleeding rates

Apr. 10, 2014 7:41 AM ETBiogen Inc. (BIIB) StockBy: Yigal Grayeff, SA News Editor
  • Biogen Idec's (NASDAQ:BIIB) Eloctate long-lasting treatment for Haemophilia A, which the company is developing with Swedish Orphan Biovitrum (Sobi), maintained low bleeding rates in children under the age of 12 in a Phase III study.
  • The results enable submission for EU approval. (PR)
  • Separately, Biogen has named Ada Koppel as Chief Strategy Officer. Koppel comes from Brookside Capital, the public-equity affiliate of Bain Capital. (PR)

Recommended For You

More Trending News

About BIIB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BIIB--
Biogen Inc.